Ophthalmology Times2h
Nordic Pharma receives CE Mark for canalicular gel Lacrifill
Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment ...
New hope for millions: Researchers find key to treating painful dry mouth disorder
Sjögren's syndrome is a chronic autoimmune disorder that affects millions worldwide, especially women, causing unrelenting ...
Verywell Health4h
Which Eye Specialist Treats Wet AMD?
Ophthalmologists specialize in wet AMD diagnosis and treatment. Learn about first steps toward diagnosis and treatment.
Contract Pharma4h
Aldeyra’s Dry Eye Drug Gets Another Rejection from the FDA
Aldeyra received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the NDA ...
InvisionMag16h
These Dry Eye Treatments Feature Groundbreaking Technology and Impressive Results
Vevye offers a semiflourinated alkane formulation that targets dry eye inflammation by enhancing the penetration of ...
My Bedtime Routine Is Simply Not Complete Without This Ridiculously Relaxing Eye Massager
For me, the Renpho eye massager is that product. I found this Bluetooth-enabled heating and massaging wonder after shelling out a gobsmacking amount of money for a heated eye massage at the doctor’s ...
Pulmonology Advisor3d
COVID And The Eye: What We’ve Learned 5 Years Since The Start of The Pandemic
Five years from the start of the COVID-19 pandemic, numerous academic studies have shown how the novel coronavirus affects ocular health.
Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug
Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease. The ...
Asianet Newsable on MSN4d
Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic
Shares of Aldeyra Therapeutics, Inc. (ALDX) slumped nearly 71% on Thursday morning after it said that the U.S. Food and Drug ...
MPR4d
FDA Denies Approval of Reproxalap for Dry Eye Disease
The Company expects to have topline data from 2 trials assessing the effect of reproxalap on dry eye disease symptoms available in the second quarter of 2025.
Stocktwits on MSN4d
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic
Shares of Aldeyra Therapeutics, Inc. (ALDX) slumped nearly 71% on Thursday morning after it said that the U.S. Food and Drug ...
US FDA declines to approve Aldeyra's eye disease drug
The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...